Is Altimmune, Inc. overvalued or undervalued?

As of 28 February 2023, the valuation grade for Altimmune, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued given its financial metrics, including a Price to Book Value of 3.21 and an EV to Sales ratio of 306.20, which are markedly high compared to industry standards. Additionally, the negative ROE of -63.48% and the negative EV to EBIT and EV to EBITDA ratios further underscore the company's financial struggles.
In comparison to its peers, Altimmune, Inc. exhibits a less favorable position, with Harpoon Therapeutics, Inc. showing a P/E of -28.51 and Graphite Bio, Inc. at -16.68, both of which are also classified as does not qualify. This suggests that Altimmune's valuation is not only high relative to its own financial performance but also compared to similar companies in the sector. Despite a recent positive stock return of 22.42% over the past month, the overall financial indicators suggest that Altimmune, Inc. remains overvalued in the current market context.